Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells
Version of Record online: 4 JUL 2013
© 2013 British Society for Immunology
Clinical & Experimental Immunology
Volume 173, Issue 2, pages 259–267, August 2013
How to Cite
Tjon, A. S. W., Tha-In, T., Metselaar, H. J., van Gent, R., van der Laan, L. J. W., Groothuismink, Z. M. A., te Boekhorst, P. A. W., van Hagen, P. M. and Kwekkeboom, J. (2013), Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clinical & Experimental Immunology, 173: 259–267. doi: 10.1111/cei.12102
- Issue online: 4 JUL 2013
- Version of Record online: 4 JUL 2013
- Accepted manuscript online: 13 MAR 2013 03:16AM EST
- Manuscript Accepted: 7 MAR 2013
- Netherlands Organization for Scientific Research
- Biotest Pharma
Fig. S1. Regulatory T cell (Treg) activation status after high-dose intravenous immunoglobulin (IVIg) treatment. Mean fluorescence intensity (MFI) of forkhead box protein 3 (FoxP3) expression in Tregs from (a) autoimmune disease patients and (b) immunodeficient patients and percentages of human leucocyte antigen D-related (HLA-DR) expression on Tregs in (c) autoimmune disease patients and (d) immunodeficient patients that are obtained before, immediately after and at day 7 after IVIg infusion. Horizontal lines represent median; n.s.: non-significant.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.